Prostate Cancer

Expectant management, which includes active surveillance and watchful waiting, is widely underused in the treatment of prostate cancer in the United States.

Daniel P. Petrylak, MD, from the Smilow Cancer Center at Yale-New Haven, describes the clinical investigation of the immunotherapeutic vaccine PROSTVAC in men with castration-resistant prostate cancer.

Howard M. Sandler, MD, from the Cedars-Sinai Medical Center, describes his excitement over research into new agents that modulate the androgen axis in prostate cancer.

A large, international study has yielded a wealth of new information about genetic alterations that can increase an individual's risk of breast, prostate, and ovarian cancer.

Studies that continue to shed light on the optimal use of sipuleucel-T in men with prostate cancer were presented at the 2013 Genitourinary Cancers Symposium.

E. David Crawford, MD, from the University of Colorado, Anschutz Medical Campus, discusses the rapidly changing treatment landscape for men with advanced prostate cancer.

Robert Dreicer, MD, MS, from the Cleveland Clinic in Ohio, discusses challenges facing the development of new lyase inhibitors and androgen receptor antagonists as treatments for men with prostate cancer.

Digital rectal examination should remain a standard for screening for prostate cancer and may even be able to identify cases of the disease that are not picked up by the PSA test.

Leonard G. Gomella, MD, form the Thomas Jefferson University Hospital Kimmel Cancer Center, discusses the novel therapeutic radium-223, which is awaiting a decision from the FDA as a treatment for men with advanced prostate cancer.

Daniel P. Petrylak, MD, from the Smilow Cancer Center at Yale-New Haven, describes a phase I/II study examining the safety and efficacy of orteronel in combination with docetaxel and prednisone in metastatic castration-resistant prostate cancer.

E. David Crawford, MD, from the University of Colorado, Anschutz Medical Campus, discusses the effectiveness of the immunotherapy sipuleucel-T as a treatment for men with advanced prostate cancer.

Robot-assisted radical prostatectomy adoption into medical practice has been swift and encompassing, even as questions remain about its efficacy, added costs, and perioperative and longer-term outcomes versus alternatives.

Howard M. Sandler, MD, the Chair of Radiation Oncology at Cedars-Sinai Medical Center, discusses radium-223, a novel alpha radiation emitting agent under evaluation by the FDA for patients with bone metastases from advanced castration-resistant prostate cancer (CRPC).

Leonard G. Gomella, MD, from the Thomas Jefferson University Hospital Kimmel Cancer Center, discusses the information currently available on sequencing the recently approved treatments for men with metastatic castration-resistant prostate cancer.

15 years after treatment, patients have roughly equal odds of experiencing declines in functions, with no significant difference associated with their choice of either radical prostatectomy or external-beam radiation therapy.

Daniel P. Petrylak, MD, from the Smilow Cancer Center at Yale-New Haven, discusses the relationship between sipuleucel-T and time to first use of an opioid analgesic in patients with metastatic castration-resistant prostate cancer.

Robert Dreicer, MD, MS, from the Taussig Cancer Institute at the Cleveland Clinic, describes potential combination therapies currently being considered as treatments for men with prostate cancer.

E. David Crawford, MD, from the University of Colorado, Anschutz Medical Campus, discusses active surveillance as a treatment approach for men with prostate cancer.

Susan F. Slovin, MD, PhD, from Memorial Sloan-Kettering Cancer Center, summarizes the development process of an effective immunotherapy for the treatment men with prostate cancer.

Hormonal therapies that target androgen are the focus of several ongoing clinical trials for the treatment of advanced prostate cancer, and as more data accrues, clinicians are gaining valuable insight as to how these drugs can best be used to manage the disease.

Following the recent flurry of FDA approvals for prostate cancer medications, oncologists are grappling with questions about which combinations or sequences of those therapies might improve outcomes for patients.

Leonard G. Gomella, MD, from the Thomas Jefferson University Hospital, describes the identification of appropriate surrogate endpoints for the evaluation of new therapies for patients with metastatic castration-resistant prostate cancer.

A novel retrospective study comparing robot-assisted radical prostatectomy and radical retropubic prostatectomy, in men with high-risk prostate cancer, found equivalent oncologic outcomes.

Matthew Cooperberg, MD, MPH, from the University of California, San Francisco, discusses the imminent stage migration that is likely to occur as new therapies become available expressly for metastatic prostate cancer.

The multidisciplinary clinic for patients with prostate and other GU cancers at Thomas Jefferson University Hospital has served as a model for other departments interested in providing multidisciplinary care.